✨
AI Summary
- Mid-cap biopharmas are increasingly acquiring to extend growth beyond initial successes.
- Companies like argenx, Insmed, and Jazz are leading this M&A trend.
- This shift impacts investors and the future of large biotechs.
Guests on This Episode
JM
Jessica Merrill
3 podcast appearances